OpenLegislation

Division 2.1.8 Co-operation between Member States (Article 3.2.d., Annex — point 1.5.)

United Kingdom

Original text. Later amendments are not shown.

Work will be carried out to follow up the high-level process of reflection on patient mobility and health care developments in the European Union and supporting the work of the High Level Group on health services and medical care. This work will involve, in particular: developing frameworks for cross-border healthcare purchasing and provision; pilot projects for European networks of centres of reference; issues relating to the mobility of health professionals; developing and piloting methodologies for health systems impact assessment; sharing best practice and expertise relating to patient safety; and supporting work on other issues of potential European cooperation, such as palliative care or proper use of pharmaceuticals. Actions may also be undertaken on ensuring the provision of supporting data and knowledge on mobility of patients and professionals as well as healthcare and long-term care systems in general. The following priorities will be addressed:

  • Strengthening information and knowledge on the quality of health systems with a special focus on patient safety, i.e. establish appropriate mechanisms for enhancing patient safety in the EU, including strengthening networking and sharing good practices in this field;

  • Analysing the financial impact of patient mobility on sending and receiving countries and the impact on financial sustainability of the health care systems involved. Supporting surveys on patient mobility focusing on the motivation for patients to move across borders and exploring the need for institutions to purchase treatment abroad for their patientsf1,

  • Collecting and providing information on cross-border care, in particular on quality, safety, sensitivity and continuity of care, patients' rights, responsibilities and liability issues;

  • Mapping, analysing and supporting pilot projects on centres of reference based on the guidelines, criteria and areas to be covered being established by the High Level Group’s Working Group on Centres of Reference;

  • Supporting the EU Health Technology Assessment network;

  • Exchange of information on therapeutic added value of new medicines and development of a model including a European database for an efficient prioritisation of medicines and medical technologyf2. Enhancing information on orphan drugs (prescription, effectiveness, efficiency and price) and their relationship to rare diseasesf3.

  • Assessing links between economics and health; investing in health and impact of better health on economic growth;

  • Collecting and providing information on an information system for primary care activity and resources to strengthen comparability of data and create a basis for routine data collection;

  • Collecting and providing information on home and residential care activity and resources information to strengthen comparability and develop time-series data;

  • Collecting and providing information on best practice on palliative care.

Annotations

Footnotes

f1

Refer to the research work currently undertaken in the area of patient mobility and quality improvement strategies.

See: http://www.iese.edu/en/events/Projects/Health/Home/Home.asp and http://www.marquis.be/Main/wp1114091605/wp1119867442

Refer also to FP6 Scientific Support to Policies, 5th Call, SSP-5A Areas 2.1 & 2.2. See: http://fp6.cordis.lu/index.cfm?fuseaction=UserSite.FP6ActivityCallsPage&ID_ACTIVITY=500

f2

Refer to Technological Platform on Innovative Medicines. See: http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed

f3

Taking account of actions carried out in the framework of Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products and the European Medicines Agency’s Committee on Orphan Medicinal Products (COMP) activities.

Notes on Division 2

Footnotes

f1

Decision No 1513/2002/EC of the European Parliament and of the Council of 27 June 2002 (OJ L 232, 29.8.2002, p. 1).

f2

Refer also to FP6 Scientific Support to Policies, 5th Call, SSP-5A Areas 2.1 & 2.2.

See: http://fp6.cordis.lu/index.cfm?fuseaction=UserSite.FP6ActivityCallsPage&ID_ACTIVITY=500

f3

Council Decision 2002/834/EC of 30 September 2002 adopting a specific programme for research, technological development and demonstration ‘Integrating and Strengthening the European Research Area’ (2002-2006) (OJ L 294, 29.10.2002, p. 1).

f4

The CORDIS web site links to the FP6 Priority 1 is http://www.cordis.lu/lifescihealth/ssp.htm

Notes on Division 2.1

Footnotes

f1

Decision No 2367/2002/EC of the European Parliament and of the Council of 16 December 2002 on the Community statistical programme 2003 to 2007 (OJ L 358, 31.12.2002, p. 1).